This review will analyze the use of clozapine in patients with neurologic illness.
Methods:
A review of the literature was performed. Attention is focused particularly on patients with seizure disorder, head injury, mental retardation, Parkinson's disease, Huntington's disease, tardive dyskinesia, and selected other neurological disorders.
Results:
This review discusses clinical difficulties/issues associated with clozapine therapy in patients with a variety of neurological disorders.
Conclusion:
Although clozapine therapy should be reserved for those patients who are refractory to conventional psychotropic medications, when used appropriately it may offer a safe and effective way of improving quality of life for patients with behavioral symptoms and neurologic illness.
KerwinR. W.The New Atypical Antipsychotics, British Journal of Psychiatry, 164, pp. 141–148, 1994.
2.
CowardD. M.ImperatoA.UrwylefS.Biochemical and Behavioral Properties of Clozapine, Psychopharmacology, 99: 86–812, 1989.
3.
KaneJ.HonigfeldG.SingerJ., and MeltzerH. Y.Clozapine for the Treatment of Resistant Schizophrenia: A Double Blind Comparison with Chlorpromazine, Archives of General Psychiatry, 45: 789–796, 1988.
4.
ChouinardG.JonesB.RemingtonG.BloomD.AddingtonD.MacEwanG. W.LabelleA.BeauclairL., and ArnottW.A Canadian Multicenter Placebo-controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients, Journal of Clinical Psychopharmacology, 13: 25–40, February 1993.
5.
LazareA., Medical Disorder in Psychiatric Populations, in Outpatient Psychiatry: Diagnosis and Treatment, Williams and Wilkins, Baltimore, Maryland, pp. 240–245, 1989.
6.
GierzM. and JesteD.Physical Comorbidity in Elderly Veterans Affairs Patients with Schizophrenia and Depression, The American Journal of Geriatric Psychiatry, 1: 165–170, 1993.
7.
MichalsM.CrismonM. L.RobertsS., and ChildsA.Clozapine Response and Adverse Effects in Nine Brain-injured Patients, Journal of Clinical Psychopharmacology, 13: 198–203, 1993.
8.
Sandoz, Inc., Clozaril (Clozapine): The Atypical Antipsychotic, Sandoz Pharmaceuticals Corp., East Hanover, New Jersey, 1990.
9.
HallerE. and BinderR. L.Clozapine and Seizures, American Journal of Psychiatry, 147: 1069–1071, 1990.
10.
SajatovicM. and MeltzerH. Y., Clozapine-induced Myoclonus and Generalized Seizures: Relation to Serotonin, in preparation.
11.
MillerD. D.Effect of Phenytoin on Plasma Clozapine Concentrations in Two Patients, Journal of Clinical Psychiatry, 52: 23–25, 1991.
12.
RaitasuoV.LehtovaaraR., and HuttunenM.Carbamazepine and Plasma Levels of Clozapine, American Journal of Psychiatry, 150: 1, January 1993.
13.
DevinskyO.HonigfeldG., and PatinJ.Clozapine-related Seizures, Neurology, 41: 369–371, 1991.
14.
GouzoulisE.ÖzdaglarA., and KasperJ.Myoclonic Seizures followed by Grand Mal Seizures during Clozapine Treatment, American Journal of Psychiatry, 150: 1128, 1993.
15.
GouzoulisE.GrunzeH., and von BardelebenU.Myoclonic Epileptic Seizures during Clozapine Treatment: A Case Report of Three Cases, European Archives of Psychiatry Clinical Neuroscience, 240: 370–372, 1991.
16.
LiukkonenJ.KoponenH., and NousiainenU.Clinical Picture and Long-term Course of Epileptic Seizures that Occur during Clozapine Treatment, Psychiatry Research, 44: 107–112, 1993.
17.
Viale-HansenS., personal communication.
18.
SajatovicM.RamirezL.KennyJ., and MeltzerH. Y.The Use of Clozapine in Borderline-intellectual Functioning and Mentally Retarded Schizophrenic Patients, Comprehensive Psychiatry, 35: 29–33, 1994.
19.
RaoJ. M.CowieV. A., and MatthewB.Tardive Dyskinesia in Neuroleptic Medicated Handicapped Subjects, Acta Psychiatry Scandinavica, 76: 507–513, 1987.
20.
PaulsonG.RizviC., and CraneG.Tardive Dyskinesia as a Possible Sequel of Long-term Therapy with Phenothiazines, Clinical Pediatric, 14: 953–955, 1975.
21.
KalachnikJ.HarderS.Kidd-NielsonP.Persistent Tardive Dyskinesia in Randomly Assigned Neuroleptic Reduction, Neuroleptic Non-reduction, and No-neuroleptic History Groups: Preliminary Results, Psychopharmacology Bulletin, 10: 27–32, 1984.
22.
BuckJ. A. and SpragueR. C.Psychotropic Medication of Mentally Retarded Residents in Community Long-term Facilities, American Journal of Mental Retardation, 93: 618–623, 1989.
23.
FactorS. A.Sanchez-RamosJ. R., and WeinerW. J.Parkinson's Disease: An Open Label Trial of Pergolide in Patients Failing Bromocriptine Therapy, Journal of Neurology, Neurosurgery, and Psychiatry, 51: 529–533, 1988.
24.
CelesiaG. G. and BarrA. N.Psychosis and Other Psychiatric Manifestations of Levodopa Therapy, Archives of Neurology, 23: 193–200, 1970.
25.
OstergaardK. and DupontE.Clozapine Treatment of Drug-induced Psychotic Symptoms in Late Stages of Parkinson's Disease, Acta Neurology Scandinavica, 78: 349–350, 1988.
26.
FactorS. and BrownD.Clozapine Prevents Recurrence of Psychosis in Parkinson's Disease, Movement Disorders, 7: 125–131, 1992.
27.
PakkenbergH. and PakkenbergB.Clozapine Treatment of Tremor, Acta Neurology Scandinavica, 73: 295–297, 1986.
28.
BennettJ. P.LandowE. R., and SchuhC. A.Suppression of Dyskinesias in Advanced Parkinson's Disease, Neurology, 43: 1551–155, 1993.
29.
SaffermanA.KaneJ.AronowitzJ.GordonM.PollackS., and LiebermannJ.The Use of Clozapine in Neurologic Disorders, Journal of Clinical Psychiatry, 55: 98–101, 1994.
30.
BruynG. W., Huntington's Chorea: Historical, Clinical, and Laboratory Synopsis, in Handbook of Clinical Neurology, Vol. 6, VinkenP. J. and BruynG. W. (eds.), Wiley, New York, pp. 632–693, 1968.
BoltM.Huntington's Chorea in the West of Scotland, British Journal of Psychiatry, 116: 259–210, 1970.
33.
FolsteinS.AbbottM.ChaseG. A.JensenB. A., and FolsteinM. F.The Association of Affective Disorder with Huntington's Disease in a Case Series and in Families, Psychiatric Medicine, 13: 537–542, 1983.
34.
FolsteinS. E., The Psychopathology of Huntington's Disease, in Genes, Brain and Behavior, McHughP. R. and McKusickV. A. (eds.), Raven Press, Ltd., New York, 1991.
35.
YoungA. B.ShoulsonI.PenneyJ. B.Huntington's Disease in Venezuela: Neurological Features and Functional Decline, Neurology, 36: 244–249, 1986.
36.
CaineE. D.PoliskyR. J.KartzinelR., and EbertM. H.The Trial Use of Clozapine for Abnormal Involuntary Movement Disorders, American Journal of Psychiatry, 136: 317–320, 1979.
37.
SajatovicM.VerbanacP.RamirezL., and MeltzerH. Y.Clozapine Treatment of Psychiatric Symptoms Resistant to Neuroleptic Treatment in Patients with Huntington's Chorea, Neurology, 41: 156, 1991.
38.
ChackoR. C.HurleyR. A., and JankovicJ.Clozapine Use in Diffuse Lewy Body Disease, Journal of Neuropsychiatry, 5: 206–208, 1993.
39.
ParsaM. and SimonM.Psychiatric Manifestations of Olivo-ponto-cerebellar Atrophy and Treatment with Clozapine, International Journal of Psychiatry in Medicine, 23: 149–156, 1993.
40.
OberholzerA. F.HendriksenC.MonschA. U.HeierlB., and StähelinH. B.Safety and Effectiveness of Low-dose Clozapine in Psychogeriatric Patients: A Preliminary Study, International Psychogeriatrics, 4: 187–195, 1992.
41.
KaneJ. M.WoernerM.LiebermanJ. A.Tardive Dyskinesias and Drugs, Drug Development Research, 9: 41–51, 1986.
42.
KaneJ. M. and SmithJ. M.Tardive Dyskinesia: Prevalence and Risk Factors, 1959 to 1979, Archives of General Psychiatry, 39: 473–478, 1982.
43.
JesteD. V. and WyattR. J.Changing Epidemiology of Tardive Dyskinesia: An Overview, American Journal of Psychiatry, 138: 291–309, 1981.
44.
KaneJ. M.WoernerM. G.PollackS.SaffermanA. Z., and LiebermanJ. A.Does Clozapine Cause Tardive Dyskinesia, Journal of Clinical Psychiatry, 54: 327–330, 1993.
45.
SmallJ. G.MilsteinV. M.MarhenkeJ. D.HallD. D., and KellamsJ. J.Treatment Outcome with Clozapine in Tardive Dyskinesia, Neuroleptic Sensitivity, and Treatment-resistant Psychosis, Journal of Clinical Psychiatry, 48: 263–216, 1987.
46.
LiebermanJ. A.SaltzB. L.JohnsC. A.PollackS.BorensteinM., and KaneJ.The Effects of Clozapine on Tardive Dyskinesia, British Journal of Psychiatry, 158: 503–510, 1991.
47.
TammingaC. A.ThakerG. K.MoranM.KakigaT., and GaoX. M.Clozapine in Tardive Dyskinesia: Observations from Human and Animal Model Studies, Journal of Clinical Psychiatry, 55(Supplement B): 102–106, 1994.
48.
SaffermanA.LiebermannJ.KaneJ.SzymanskiS., and KinonB.Update on the Clinical Efficacy and Side Effects of Clozapine, Schizophrenia Bulletin, 17: 247–2611991.
49.
NaberD.LeppigM.GrohmannR., and HippiusH.Efficacy and Adverse Effects in the Treatment of Schizophrenia and Tardive Dyskinesia—A Retrospective Study of 387 Patients, Psychopharmacology, 99: 573–576, 1989.
50.
GrohmannR.RutherE.SassimN., and SchmidtL. G.Adverse Effects of Clozapine, Psychopharmacology, 99: 5101–5104, 1989.
51.
KonafskyD. and LindemayerJ. P.Relapse Following Lorazepam Withdrawal, American Journal of Psychiatry, 150: 348–349, 1993.
52.
PeacockL. and GerlachJ.Clozapine Treatment in Denmark: Concomitant Psychotropic Medication and Hematologic Monitoring in a System with Liberol Usage Practices, Journal of Clinical Psychiatry, 55: 44–49, 1994.
53.
LeadbetterR.ShuttyM.PavalonisD.ViewingV.HigginsP., and DownsM.Clozapine-induced Weight Gain: Prevalence and Clinical Relevance, American Journal of Psychiatry, 149: 68–12, 1992.
54.
LiebermannJ.JohnsC.KaneJ.RaiK.PisciottaA.SaltzB., and HowardA.Clozapine-induced Agranulocytosis: Non-cross Reactivity with Other Psychotropic Drugs, Journal of Clinical Psychiatry, 49: 271–277, 1988.
55.
KruppP. and BarnesP.Leponex-associated Granulocytopenia: A Review of the Situation, Psychopharmacology, 99(Suppl.): 5118–5121, 1989.
56.
AlvirJ.LiebermannJ.SaffermanA.SchwimmerJ., and SchaafJ.Clozapine-induced Agranulocytosis, The New England Journal of Medicine, 329: 162–167, 1993.
57.
LiebermannJ. A.YunisJ.EgeaE.CanosoR. T.KaneJ. M., and YunisE. J.HLA-B38, DR 4, DQW 3 and Clozapine-induced Agranulocytosis in Jewish Patients with Schizophrenia, Archives of General Psychiatry, 47: 945–948, 1990.
58.
WeideR.KopplerH.PflugerK. H.Successful Treatment of Clozapine-induced Agranulocytosis with Granulocyte-colony Stimulating Factor (G-CSF), British Journal of Hematology, 80: 557–559, 1992.
59.
GersonS. L.GullionG.YehH.-S., and MasonC.Granulocyte Colony-stimulating Factor for Clozapine-induced Agranulocytosis, The Lancet, 340: 1097, 1992.
60.
BauerM. and MacKertA.Clozapine Treatment after Agranulocytosis Induced by Classic Neuroleptics, Journal of Clinical Psychopharmacology, 14: 71–73, 1994.
